COVID-19 Evidenzsynthesen und Leitlinienempfehlungen

Published by AWMF/CEO-sys Koordinierende on May 19, 2021

Disclaimer

Sponsors

Contact

Abstract

Evidenzbasierte Handlungsempfehlungen zu diagnostischen und therapeutischen sowie Public Health Fragestellungen zu COVID-19 ambulant und stationär

Language

de

PICOS

PICO 2.1

Population
All adult patients (with or without risk factors for COVID-19) with positive PCR test for SARS-CoV-2
Intervention
Systematic Steroids
Comparator
keine oder symptomatische Standardtherapie
Outcomes

PICO 2.2

Population
All adult patients (with or without risk factors for COVID-19) with positive PCR test for SARS-CoV-2
Intervention
Systematic Steroids
Comparator
keine oder symptomatische Standardtherapie
Outcomes

PICO 2.3

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and asymptomatic or mild disease
Intervention
Colchicine with standard care
Comparator
Standard care with or without placebo
Outcomes

PICO 3.1

Population
All adult in-hospital patients with confirmed SARS-CoV-2 infection
Intervention
Treatment with Remdesivir
Comparator
Standard of Care
Outcomes

PICO 3.2

Population
All adult in-hospital patients with confirmed SARS-CoV-2 infection
Intervention
Treatment with Remdesivir
Comparator
Standard of Care
Outcomes

PICO 3.3

Population
All adult in-hospital patients with confirmed SARS-CoV-2 infection
Intervention
Corticosteroids
Comparator
Standard of Care
Outcomes

PICO 3.4

Population
All adult in-hospital patients with confirmed SARS-CoV-2 infection
Intervention
Corticosteroids
Comparator
Standard of Care
Outcomes

PICO 3.5

Population
Hospitalised patients with confirmed SARS-CoV-2 infection
Intervention
Convalescent plasma
Comparator
Standard of Care or Placebo
Outcomes

PICO 3.6

Population
Hospitalised patients with confirmed SARS-CoV-2 infection
Intervention
Convalescent plasma
Comparator
Standard of Care or Placebo
Outcomes

PICO 3.7

Population
Patients with severe/critical COVID-19 (WHO Kategorie: Severe Disease)
Intervention
Noninvasive Mechanical Ventilation
Comparator
Early Invasive Ventilation Mechanical Ventilation (without preceding Noninvasive Mechanical Ventilation attempts)
Outcomes

PICO 3.8

Population
Patients with severe/critical COVID-19 (WHO Kategorie: Severe Disease)
Intervention
Noninvasive Mechanical Ventilation
Comparator
Early Invasive Ventilation Mechanical Ventilation (without preceding Noninvasive Mechanical Ventilation attempts)
Outcomes

PICO 3.9

Population
Hospitalised patients with confirmed SARS-CoV-2 infection and with severe disease, according to the WHO clinical progression score (≥6)
Intervention
Therapeutic anticoagulant
Comparator
Standard of Care (prophylactic anticoagulant)
Outcomes

PICO 3.10

Population
Hospitalised patients with confirmed SARS-CoV-2 infection and with severe disease, according to the WHO clinical progression score (≥6)
Intervention
Therapeutic anticoagulant
Comparator
Standard of Care (prophylactic anticoagulant)
Outcomes

PICO 3.11

Population
Hospitalised patients with moderate/critical COVID-19 infection (according to WHO clinical progression score 4-6)
Intervention
Vitamin D supplementation
Comparator
Standard of Care or Placebo
Outcomes

PICO 3.12

Population
Hospitalised patients with moderate/critical COVID-19 infection (according to WHO clinical progression score 4-6)
Intervention
Vitamin D supplementation
Comparator
Standard of Care or Placebo
Outcomes

PICO 3.13

Population
All adult in-hospital patients with confirmed or suspected SARS-CoV-2 infection
Intervention
Azithromycin
Comparator
Standard of Care
Outcomes

PICO 3.14

Population
All adult in-hospital patients with confirmed or suspected SARS-CoV-2 infection
Intervention
Azithromycin
Comparator
Standard of Care
Outcomes

PICO 3.15

Population
Hospitalised patients with confirmed SARS-CoV-2 infection and with moderate disease, according to the WHO clinical progression score (= WHO clincal progression score 4)
Intervention
Ivermectin
Comparator
Placebo
Outcomes

PICO 3.16

Population
Hospitalised patients with confirmed SARS-CoV-2 infection and with moderate disease, according to the WHO clinical progression score (= WHO clincal progression score 4)
Intervention
Ivermectin
Comparator
Placebo
Outcomes

PICO 3.17

Population
All adult in-hospital patients with confirmed or suspected SARS-CoV-2 infection
Intervention
SARS-CoV-2 specific monoclonal antibodies
Comparator
Placebo
Outcomes

PICO 3.18

Population
All adult in-hospital patients with confirmed or suspected SARS-CoV-2 infection
Intervention
SARS-CoV-2 spezifische Antikörper
Comparator
Placebo
Outcomes

PICO 3.19

Population
All adult in-hospital patients with confirmed SARS-CoV-2 infection
Intervention
Tocilizumab+Standard of Care
Comparator
Standard of Care(+Placebo)
Outcomes

PICO 3.20

Population
Patients with a confirmed diagnosis of COVID-19 receiving interventions for palliative symptom control, with no age, gender or ethnicity restrictions
Intervention
Multi-modal pharmacological interventions for palliative symptom control (including bit not limited to opioids, antiemetics, antimuscarinics, and benzodiazepines)
Comparator
N/A
Outcomes

PICO 3.21

Population
All adult in-hospital patients with confirmed SARS-CoV-2 infection
Intervention
Treatment with Anakinra
Comparator
Standard of Care
Outcomes

PICO 3.22

Population
Hospitalised patients with confirmed SARS-CoV-2 infection
Intervention
Intermediate Dose Anticoagulation
Comparator
Standard of Care (prophylactic anticoagulant)
Outcomes

PICO 3.23

Population
Adult in-hospital patients not hospitalised due to COVID-19
Intervention
SARS-CoV-2 specific monoclonal antibody: bamlanivimab
Comparator
Placebo
Outcomes

PICO 3.24

Population
Adult in-hospital patients not hospitalised due to COVID-19
Intervention
SARS-CoV-2 specific monoclonal antibody: bamlanivimab and etesevimab
Comparator
Placebo
Outcomes

PICO 6.1

Population
Healthcare workers (eg, physicians, nurses); adults (≥18 years); irrespective of sex, health status, or country; diverse settings of study conduction eligible (eg, clinical setting, outpatient setting)
Intervention
Exposure to COVID-19 pandemic (ie, survey period after the first officially registered SARS-CoV-2 case in the respective country based on national infection dates published by the World Health Organization); irrespective of medical care for COVID-19 patients (ie, level of contact)
Comparator
No exposure to COVID-19 pandemic (ie, before first officially registered SARS-CoV-2 case in the respective country based on national infection dates published by the WHO)
Outcomes

PICO 6.2

Population
Healthcare workers (eg, physicians, nurses); adults (≥18 years); irrespective of sex, health status, or country; diverse settings of study conduction eligible (eg, clinical setting, outpatient setting)
Intervention
Intervention conducted in anticipation of, during, or in the aftermath of SARS-CoV 2 pandemic outbreak: psychological and non-psychological (eg, pharmacological, exercise), intervention intended to foster mental health and psychosocial support, resilience (or related constructs; eg, hardiness, posttraumatic growth, psychological adjustment) and/or stress management; focus on improving the participants’ ability to cope with the various stressors of a pandemic (eg, symptoms and death, quarantine); any setting (eg, individual or group setting); any delivery format (eg, face-to-face or online); irrespective of content, theoretical foundation (eg, cognitive-behavioral therapy, mindfulness) and duration
Comparator
No selection criteria
Outcomes